I NUOVI AGENTI ANTIVIRALI PER IL COVID-19: UNA OTTIMA RIFLESSIONE DA “NATURE REVIEWS” (FREE)
A tale of two antiviral targets — and the COVID-19 drugs that bind them The FDA is considering authorizations for Pfizer’s paxlovid and Merck & Co.’s molnupiravir, the first two oral COVID-19 antivirals. Megan Cully COVID-19, for all of the problems it has created, has shown the unprecedented speed with which drug developers can move.…